Page 1

ABCAM PLC Interim results 8.3 % constant currency revenue growth in H1 as customers gradually return to labs 8 March 2021 , Cambridge , UK - Abcam plc ( Nasdaq : ABCM ; AIM : ABC ) ( " Abcam " , the " Group " or the " Company " ) , a global leader in the supply of life science research tools , today announces its interim results for the six month period ended 31 December 2020 ( " H1 2021 " ) . SUMMARY PERFORMANCE Revenue Gross profit margin , % Operating profit Profit Before Tax ( PBT ) Diluted earnings per share ( EPS ) ( pence ) Net Cash * ● ● * Net Cash comprises cash and cash equivalents less borrowings . FINANCIAL HIGHLIGHTS ● ● abcam ● ● O Reported H1 2021 £ m 147.5 70.9 % 15.5 13.8 5.3p 211.9 O H1 2020 £ m 138.2 69.7 % 26.6 26.0 12.6p 88.5 Adjusted¹ H1 2021 £ m 147.5 70.9 % 23.6 21.9 8.1p 211.9 H1 2020 £ m 138.2 69.7 % 33.4 32.8 Total revenue growth of 6.7 % on a reported basis and 8.3 % at Constant Exchange Rates ( CER ) ¹ Catalogue revenue of £ 139.0m , growth of 7.8 % at CER 13.0p 88.5 O Custom Products & Licensing ( CP & L ) revenue of £ 8.5m , growth of 15.9 % at CER Total in - house product revenue growth of 24.5 % at CER ( includes CP & L ) ( H1 2020 : 11.3 % ) Gross margin increased 120 basis points , benefiting from the contribution of higher margin in - house products Operating profit of £ 15.5m ( H1 2020 : £ 26.6m ) and adjusted ' operating profit of £ 23.6m ( H1 2020 : £ 33.4m ) , equating to an adjusted operating margin of 16.0 % ( H1 2020 : 24.2 % ) reflecting planned investments to support the Group's long - term growth strategy , as well as the impact of COVID - 19 STRATEGIC & OPERATIONAL HIGHLIGHTS Customers gradually returned to labs in H1 , although according to industry research , almost 60 % of life science labs were still operating below normal capacity through December 2020 Improved customer engagement levels , reflecting our ongoing focus on supporting customers through the pandemic O Average customer transactional Net Promotor Score ( tNPS ) in the first six months of +59 , up 7 % pts year - on - year Reported diluted EPS of 5.3p ( H1 2020 : 12.6p ) and adjusted¹ diluted EPS of 8.1p ( H1 2020 : 13.0p ) reflecting the decrease in operating profit and increase in the number of ordinary shares in issue Net cash inflow from operating activities of £ 33.9m ( H1 2020 : £ 39.6m ) , ending the period with a net cash position of £ 211.9m ( H1 2020 : £ 88.5m ) Employee engagement remains high as we continue to support the health and wellbeing of our teams O Externally recognized by Glassdoor , the employer review website , as the 3rd best place to work in the UK in 2020 and the 2nd highest rated CEO of a UK business during the pandemic Delivered operational progress across all areas of our strategic growth plan , including : O Innovated and published over 2,500 new in - house recombinant antibody products and expanded our in - house conjugation , recombinant proteins and engineered cell line ranges O New in - house product introductions significantly up on H1 2020 , although certain product development pipelines have slowed due to reduced lab capacity across our global facilities resulting from COVID - 19 restrictions